|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jay T. Flatley||Exec. Chairman||1,26M||N/D||1953|
|Mr. Francis A. deSouza||CEO, Pres & Director||N/D||N/D||1971|
|Mr. Sam A. Samad||CFO & Sr. VP||896,83k||N/D||1970|
|Mr. Omead Ostadan||Chief Product & Marketing Officer||N/D||N/D||1972|
|Ms. Aimee L. Hoyt||Chief People Officer & Sr. VP||956,45k||N/D||1971|
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. It also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a collaboration with Roche to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology. The company operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, China, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Illumina, Inc. al 3 febbraio 2020 è 5. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 5; diritti degli azionisti: 5; retribuzione: 8.